Oncology Views & Analysis

Views & Analysis

Oncology

pharmaphorum podcast Episode 211, ESMO25: Boehringer Ingelheim

ESMO25: Patient-centric oncological futures with Boehringer ...

On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.

Oncology

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

Oncology

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.

Oncology

Chemicals in test tubes on a rack in a lab

Advancing radiopharmaceutical development: Preclinical preci...

Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.

Oncology

News and advice from an investor-CEO, with Milenko Cicmil

pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.

Oncology

The cancer community must seize the opportunity of the Natio...

With the government’s National Cancer Plan due for publication this autumn, we have an opportunity to fundamentally improve how we deliver innovation.

ESMO25: Patient-centric oncological futures with Boehringer ...

ESMO 2025 commences: ADCs, AI, and Asia

Pre-ESMO insights: Corcept on platinum-resistant ovarian can...

Advancing radiopharmaceutical development: Preclinical preci...

News and advice from an investor-CEO, with Milenko Cicmil

The cancer community must seize the opportunity of the Natio...

Lilly gets back in infectious disease, via three M&A deals

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks